【摘要】 目的:探讨规范应用阿片受体激动剂控制癌痛的临床合理性和实用性。方法:2012年1月-2014年1月,入选南平市第一医院肿瘤内科中重度疼痛实体肿瘤患者387例,收集临床相关资料,采用t检验、单因素方差分析、卡方检验分析规范应用阿片受体激动剂与经验应用阿片受体激动剂对控制癌痛的治疗效果。结果:规范用药癌痛控制良好率(78.4%)明显高于经验用药(32.9%)(χ~2=78.562,P=0.000);规范用药的疼痛评分、住院天数明显低于经验用药(P=0.000);癌痛规范用药绐疗中,年龄、性别差异无统计学意义;经验用药的剂量和加药速度明显高于规范用药。结论:规范应用阿片受体激动剂控制癌痛更为科学合理,具有临床实用性。更多还原

【Abstract】 OBJECTIVE To investigate the clinical rationality and the clinical practicability through opioid agonist standardized medication.METHODS A total of 387 malignant tumor patients above moderately chronic pain were enrolled from the Medical Oncology Department of Nanping First Hospital from January 2012 to January 2014,and patients’ information was collected,T test,single factor analysis of variance,chi-square test were performed to test the pain control effect of opioid agonist therapies compared between standardized medication and empirical medication.RESULTS The standardized opioid agonist medication(78.4%)was significant higher than the empirical medication(32.9%)in tumor pain control rate(χ~2=78.562,P=0.000);The pain score,hospitalization days of the standard medication were obviously lower than that of the empirical medication(P=0.000);Age and gender were no statistical significance compared between the standard medication and the empirical medication;increasing dosage and speed of the empirical medication were significantly higher than that of the standard medication.CONCLUSION The standardized medication of opioid agonis is scientific and reasonable and applicable method for clinical tumor treatment.更多还原